Solid quarter; awaiting further insight on SNY alliance opportunities

Research evidence excerpt

Solid quarter; awaiting further insight on SNY alliance opportunities

Update

July 30, 2026 07:04 PM GMT

Morgan Stanley & Co. LLCMRegeneron Pharmaceuticals Inc. | North America Terence C Flynn, Ph.D.

Equity Analyst

Solid quarter; awaiting further Terence.Flynn@morganstanley.comChris Yu, J.D., Ph.D. +1 212 761-2230

Chris.L.Yu@morganstanley.com +1 212 761-2535

insight on SNY alliance Connor M Massari

Connor.Massari@morganstanley.com +1 212 761-2417

opportunities Alexander Yevdokimov, Ph.D.

Research Associate

What’s Changed Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

Hailey Horowitz

Regeneron Pharmaceuticals Inc. (REGN.O) From To Research Associate

Price Target $730.00 $758.00 Hailey.Horowitz@morganstanley.com +1 212 761-5264

Damien H Kerner

AlphaSignals Earnings Reaction Damien.H.Kerner@morganstanley.com +1 212 761-3829

Unchanged Meaningful upside Modest revision higher Morgan Stanley India Company Private Limited+

Impact to our thesis Financial results versus consensus Direction of next 12-month Saket Agarwal

consensus EPS Research Associate

Source: Company data, Morgan Stanley Research Saket.Agarwal@morganstanley.com +91 22 6995-4012

REGN delivered a solid 2Q beat, led by Dupi, Eylea and Libtayo. Regeneron Pharmaceuticals Inc. (REGN.O, REGN US)

REGN and partner SNY (on their respective EPS calls) both Biotechnology | United States of America

Stock Rating Equal-weight

noted openness to additional collaboration opportunities, Industry View Attractive

emphasizing the alliance’s strategic importance. PriceShr price,targetclose (Jul 29, 2026) $758.00$695.42

Mkt cap, curr (mm) $75,105

REGN posted a solid 2Q beat on both revenue and EPS, driven by Dupi, Eylea, 52-Week Range $821.11-541.00

and Libtayo (see our first take HERE).